GlassScriptPhysician profile
Thomas M Helton
NPI 1881624450
$12,822.96
in general payments reported to CMS, 2019-2025
70 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,040 · 2020: $1,781 · 2021: $2,169 · 2022: $2,006 · 2023: $1,902 · 2024: $1,458 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,828.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,320.36 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,142.23 | 2021-2025 | |
| Novo Nordisk INC | $935.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $819.26 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $730.69 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $700.45 | 2019-2025 | |
| Astellas Pharma US INC | $640.97 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $622.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $557.13 | 2019-2024 | Synjardy, Jardiance |
| Lilly USA, LLC | $502.45 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Allergan, INC. | $365.29 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $359.17 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $358.02 | 2019-2021 | |
| Boston Scientific Corporation | $320.30 | 2022-2025 | Wavewriter Alpha Prime 16, General - Erectile Dysfunction |
| Eisai INC. | $249.74 | 2020-2024 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Helton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.